Cytokinetics (CYTK) Misses Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $68.78 -1.63%
Revenue Growth %: +1,966.3%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +1,966.3%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($0.23), $0.11 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $10.1 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- Barclays says AI trade is maturing, favors greater diversification
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
